Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Synaffix Has Announced The Expansion Of Its License Agreement With Macrogenics Adding Up To Four Antibody-drug Conjugates Programs; Expanded Collaboration Includes Up To $2.2B In Total Potential Payments

The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net